Inhibikase Therapeutics Inc (IKT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inhibikase Therapeutics Inc (IKT) has a cash flow conversion efficiency ratio of -0.145x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.59 Million) by net assets ($72.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see IKT market cap for the company's overall valuation and market capitalisation.
Inhibikase Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Inhibikase Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Inhibikase Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inhibikase Therapeutics Inc ranked by their cash flow conversion efficiency. See IKT debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sun Yad Construction Co Ltd
TW:1316
|
-0.040x |
|
VivoPower PLC
NASDAQ:VIVO
|
N/A |
|
Tempore Properties SOCIMI SAU
MC:YTEM
|
0.013x |
|
Khonburi Sugar Public Company Limited
BK:KBS
|
0.252x |
|
The E&M Co. Ltd
KQ:089230
|
-0.116x |
|
Air Busan Co Ltd
KO:298690
|
0.154x |
|
White Pearl Acquisition Corp.
NYSE:WPAC
|
-0.097x |
|
PT Indonesia Kendaraan Terminal Tbk
JK:IPCC
|
0.066x |
Annual Cash Flow Conversion Efficiency for Inhibikase Therapeutics Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Inhibikase Therapeutics Inc from 2016 to 2024. View Inhibikase Therapeutics Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $94.87 Million | $-19.15 Million | -0.202x | +87.75% |
| 2023-12-31 | $10.98 Million | $-18.09 Million | -1.647x | -99.72% |
| 2022-12-31 | $21.04 Million | $-17.35 Million | -0.825x | -121.63% |
| 2021-12-31 | $38.42 Million | $-14.30 Million | -0.372x | -222.43% |
| 2020-12-31 | $9.78 Million | $-1.13 Million | -0.115x | -253.20% |
| 2019-12-31 | $-4.49 Million | $-338.29K | 0.075x | +108.20% |
| 2018-12-31 | $-777.97K | $714.99K | -0.919x | -1147.82% |
| 2017-12-31 | $-1.44 Million | $-126.39K | 0.088x | +300.90% |
| 2016-12-31 | $-1.35 Million | $-29.57K | 0.022x | -- |
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a p… Read more